51 results
8-K
EX-99.2
VANI
Vivani Medical Inc
14 Nov 23
Results of Operations and Financial Condition
6:06am
therapy for the
treatment of chronic weight management in obese or overweight patients
Vivani is actively engaged in discussions with the US FDA to enable … and improve patient outcomes in the treatment of chronic diseases.
“At Vivani, we continue to make progress in the development of our pipeline
8-K
EX-99.2
VANI
Vivani Medical Inc
28 Feb 24
Regulation FD Disclosure
8:30am
under development for the treatment of chronic weight management in obese or overweight patients and type 2 diabetes, respectively. NPM - 139 … (semaglutide implant) is also under development for chronic weight management with the added potential benefit of once - yearly administration. An innovative
8-K
EX-99.1
VANI
Vivani Medical Inc
26 Mar 24
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
8:31am
the development of GLP-1 implants for the treatment of obesity
and chronic weight management
Positive NPM-115 (exenatide implant) preclinical weight … for chronic weight management in obese or overweight patients with one or more risk factors, today reported financial results for the fourth quarter and full
8-K
EX-99.2
VANI
Vivani Medical Inc
26 Mar 24
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
8:31am
programs NPM - 115 and NPM - 119 are miniature, six - month, GLP - 1 (exenatide) implants under development for the treatment of chronic weight management … in obese or overweight patients and type 2 diabetes, respectively. NPM - 139 (semaglutide implant) is also under development for chronic weight
8-K
EX-99.1
VANI
Vivani Medical Inc
28 Feb 24
Regulation FD Disclosure
8:30am
implants in development for chronic weight management designed to guarantee medication adherence and potentially improve treatment tolerability by providing … preclinical data on weight loss effects for NPM-115, the Company’s miniature, twice-yearly, exenatide implant under development for the treatment of chronic
8-K
EX-99.1
iwp80
2 Sep 22
Entry into a Material Definitive Agreement
3:42pm
8-K
EX-99.1
gqgze4g mbktg
6 Mar 24
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
8:30am
8-K
EX-99.1
x1pl5tyy2tf7bts
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
8-K
EX-99.1
3fb 31336
14 Nov 23
Results of Operations and Financial Condition
6:06am
425
EX-99.1
pbhu7 tcjgdvd
29 Jul 22
Business combination disclosure
9:07am
8-K
EX-99.1
oonezg4o0tlpgkj
29 Jul 22
Submission of Matters to a Vote of Security Holders
9:05am
8-K
EX-99.2
i7u7xpx 3dl8
15 May 23
Results of Operations and Financial Condition
6:49am
8-K
EX-99.1
54qn2 1b2v
8 Feb 22
Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company
12:00am
425
EX-99.1
6rgrp6c47ahry re0x
8 Feb 22
Business combination disclosure
12:00am
8-K
qniyryihno5n0
28 Feb 24
Regulation FD Disclosure
8:30am
8-K
EX-99.1
jbhd2tbeqmjkt l6un
17 Oct 22
Regulation FD Disclosure
6:45am
8-K
EX-99.1
xnz e38sy
15 May 23
Results of Operations and Financial Condition
6:49am
8-K
EX-99
h8cofttqgalvvzc7zk9
25 Jul 16
Second Sight Announces Positive Five-Year Data from Argus II Retinal Prosthesis System
12:00am